OBESITY TREATMENT AGENTS PRIOR AUTHORIZATION FORM

(form effective 1/8/2024)







Fax to PerformRx[™] at **1-855-851-4058**, or to speak to a representative call **1-866-907-7088**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
□ New request □ Renewal request	# of pages:		
Prescriber name:			
Specialty:	NPI:	State license #:	
Street address:	City/state/zip:		
Phone:	Fax:		
Name of office contact:			
Contact's phone number:	LTC facility contact/phone:		
Beneficiary name:	Beneficiary ID#:	Date of birth:	
CLINICAL INFORMATION			
Drug requested:			
Strength & package size:	Quantity:	Refills:	
Directions:			
Diagnosis (submit documentation):		DX code (required):	
For a non-preferred Obesity Treatment Agent, does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agent appropriate for the beneficiary's diagnosis or indication? Refer to https://papdl.com/ preferred-drug-list for a list of preferred and non-preferred drugs in this class.		🗆 Yes	Submit
		□ No	documentation.
Does the beneficiary have any contraindications to the requested medication?		🗆 Yes	Submit
		🗆 No	documentation.
ATTESTATION from the prescriber: Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?		□ Yes	
		□ No	

Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.

INITIAL REQUESTS					
1. The beneficiary is <u>18 years of age or</u>	older: Pre-treatment weight:	Pre-treatme	Pre-treatment BMI:		
 Has a BMI greater than or equal to 30 kg/m2 Has a BMI greater than or equal 27 kg/m2 and less than 30 kg/m2 and at least one of the following weight-related comorbidities: 					
☐ dyslipidemia ☐ hypertension	 metabolic syndrome obstructive sleep apnea 	 prediabetes type 2 diabetes 	□ other (list):		
Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. and has at least one of the following weight-related comorbidities:					
 □ dyslipidemia □ hypertension 	 metabolic syndrome obstructive sleep apnea 	 prediabetes type 2 diabetes 	□ other (list):		
2. The beneficiary is less than 18 years	of age:				
Pre-treatment BMI:		Pre-treatment BMI z-score:			
□ Has a BMI in the 95th percentile or greater standardized for age and sex based on current CDC charts					
3. Request is for Evekeo (amphetamine) ODT/tablet:					
U Was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history					
U Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction					
Has a history of trial and failure of or a contraindication or an intolerance of all other Obesity Treatment Agents (preferred and non-preferred)					
□ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering					
□ For a beneficiary with a history of substance dependency, abuse, or diversion:					
Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances					
RENEWAL REQUESTS					
1. All requests: The dose of the requested medication is currently being titrated The beneficiary is experiencing clinical benefit with the requested medication					
2. The beneficiary is 18 years of age or	older: Pre-treatment weight:	Current weight:			
	of age: Pre-treatment BMI:				
Pre-treatment BMI z-score:		Current BMI z-score:			
4. Request is for Evekeo (amphetamine					
□ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering (submit documentation)					
□ For a beneficiary with <u>a history of substance dependency, abuse, or diversion</u> :					
□ Has results of a recent UDS for I with prescribed controlled subst	icit & illicit drugs with the potential for abuse (in ances	cluding specific testing for oxycodone, fer	ntanyl, and tramadol) that is consistent		
PLEASE FAX COMPLETED F	ORM WITH REQUIRED CLINICAL	DOCUMENTATION			
Prescriber signature:		Date:			
Confidentiality Notice: The documents accompanying th	s telecopy may contain confidential information belonging to the	sender. The information is intended only for the use of	the use of the individual named above. If you are not the intended recipient, you are		

hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited. CHCKF_233159912-4